LIXT Lixte Biotechnology Holdings, Inc. - 8-K

Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

On
March 18, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), and Geordan Pursglove, the Company’s Chief Executive
Officer (the “CEO”), entered into an Amendment to the Employment Agreement (the “Amendment”). The original employment
agreement (the “Employment Agreement”) between the Company and the CEO was entered in on June 16, 2025.

Pursuant
to the Amendment, the CEO’s annual base salary was increased from $240,000 to $360,000 effective as of January 1, 2026. The Amendment
was approved by the Company’s Compensation Committee and Board of Directors.

The
Amendment is being filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description
does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed herewith
as Exhibit 10.1.

Item
9.01 Financial Statements and Exhibits

(d)
Exhibits. The following exhibits are filed herewith.

Exhibit

Number

Description

10.1

Amendment to Employment Agreement dated March 18, 2026, between Lixte Biotechnology Holdings. Inc., and Geordan Purglove.

104

Cover
Page Interactive Data File (embedded within the inline XBRL Document)